BE462012A - - Google Patents

Info

Publication number
BE462012A
BE462012A BE462012DA BE462012A BE 462012 A BE462012 A BE 462012A BE 462012D A BE462012D A BE 462012DA BE 462012 A BE462012 A BE 462012A
Authority
BE
Belgium
Prior art keywords
methyl
isopropyl
allyl
barbituric acid
acid
Prior art date
Application number
Other languages
French (fr)
Publication of BE462012A publication Critical patent/BE462012A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

       

   <Desc/Clms Page number 1> 
 



  :Procédé pour la préparation de solutions aqueuses stables de sels alcalins de l'acide 1-méthyl-5-isopropyl-5-allyl-barbi- turique. 



   Le sel sodique de l'acide   1-métbyl-5-isopropyl-5-allyl-   barbiturique possède, lorsqu'il est injecté, une action immédi- ate, mais de courte durée. Il est par conséquent employé comme narcotique de brève durée en injection intra-veineuse. Les solutions aqueuses des sels alcalins de l'acide 1-méthyl-5- isopropyl-5-allyl-barbiturique ne sont stables que pendant peu 

 <Desc/Clms Page number 2> 

 de temps, de telle sorte qu'il faut les préparer immédiatement avant l'emploi. 



   On a maintenant trouvé qu'on peut obtenir des solutions aqueuses stables pendant un temps prolongé des sels alcalins 
 EMI2.1 
 de l'acide 1-méthyl-5-isopropyl-5-allôrl-barbiturique si leur préparation est faite en dissolvant l'acide 1-méthyl-5-iso- propyl-5-allyl-barbiturique dans une lessive alcaline aqueuse en présence de diéthylamide acétique. La dissolution de l'acide   1-méthyl-5-isopropyl-5-allyl-barbiturique   en substance dans le stabilisateur avant la neutralisation avec une lessive alcaline peut être facilitée par adjonction de glycérine. On peut sté- riliser ces solutions par chauffage ou par addition d'éther-sel méthylique de l'acide p-oxybenzoïque et d'éther-sel propylique de l'acide p-oxybenzoique. 



   Les solutions préparées selon ce procédé possèdent le même effet narcotique après une longue conservation et la même toxicité que les solutions fraîchement préparées. Tandis qu'une solution aqueuse   à   la% du sel sodique de l'acide 1-   méthyl-5-isopropyl-5-allyl-barbiturique,   chauffée pendant 17 heures à 100  C, se trouble fortement par séparation de produits de décomposition sous forme de gouttes, la solution stabilisée avec la diéthylamide acétique reste limpide et in- colore après le même traitement. L'analyse montre que dans la solution non stabilisée 18,4% du produit de départ sont détruits, tandis que cette décomposition n'est que de   6%   dans la solution stabilisée.

   Dans une solution stabilisée conser- vée pendant 4 semaines à 23 C, on n'a pas pu constater de pro- duits de décomposition. 



   Les solutions stabilisées avec la diéthylamide acétique de sels alcalins de l'acide   1-méthyl-5-isopropyl-5-allyl-   barbiturique peuvent être utilisées comme médicament. 

 <Desc/Clms Page number 3> 

 



   Exemple. 



   9,15 parties en poids d'acide   1-méthyl-5-isopropyl-5-   allyl-barbiturique sont dissoutes dans un mélange de 18 parties en poids de diéthylamide acétique et 9,5 parties en poids de    glycérine à 85% environ, en chauffant légèrement ; solution   limpide est refroidie et additionnée de 40 parties en volume de lessive de soude n. La solution est complétée à 100 par- ties en volume avec de l'eau distillée et, après filtration, remplie en ampoules et stérilisée. 



   Au lieu de la stérilisation par chauffage, on peut aussi obtenir des solutions stériles, si l'on ajoute   à   celles- ci avant la filtration 0,08 partie en poids d'éther-sel méthylique de l'acide   p-oxybenzolque   et 0,01 partie en poids d'éther-sel propylique de l'acide   p-oxybenzoïque.  



   <Desc / Clms Page number 1>
 



  : Process for the preparation of stable aqueous solutions of alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid.



   The sodium salt of 1-metbyl-5-isopropyl-5-allyl-barbituric acid has, when injected, an immediate action, but of short duration. It is therefore used as a short-acting narcotic by intravenous injection. Aqueous solutions of the alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid are only stable for a short time.

 <Desc / Clms Page number 2>

 time, so that they must be prepared immediately before use.



   It has now been found that aqueous solutions which are stable over a prolonged period of time of the alkali salts can be obtained.
 EMI2.1
 1-methyl-5-isopropyl-5-allorl-barbituric acid if their preparation is made by dissolving 1-methyl-5-isopropyl-5-allyl-barbituric acid in an aqueous alkaline solution in the presence of acetic diethylamide. Dissolution of 1-methyl-5-isopropyl-5-allyl-barbituric acid in substance in the stabilizer prior to neutralization with alkaline lye can be facilitated by addition of glycerin. These solutions can be sterilized by heating or by adding p-oxybenzoic acid methyl ether salt and p-oxybenzoic acid propyl ether salt.



   Solutions prepared by this process have the same narcotic effect after long storage and the same toxicity as freshly prepared solutions. While a 1% aqueous solution of the sodium salt of 1-methyl-5-isopropyl-5-allyl-barbituric acid, heated for 17 hours at 100 ° C., becomes highly cloudy on separation of decomposition products in the form of drops, the solution stabilized with acetic diethylamide remains clear and colorless after the same treatment. Analysis shows that in the unstabilized solution 18.4% of the starting material is destroyed, while this decomposition is only 6% in the stabilized solution.

   In a stabilized solution stored for 4 weeks at 23 ° C., no decomposition products could be observed.



   Solutions stabilized with acetic diethylamide of alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid can be used as a medicament.

 <Desc / Clms Page number 3>

 



   Example.



   9.15 parts by weight of 1-methyl-5-isopropyl-5-allyl-barbituric acid are dissolved in a mixture of 18 parts by weight of acetic diethylamide and 9.5 parts by weight of approximately 85% glycerin, in heating slightly; clear solution is cooled and added with 40 parts by volume of sodium hydroxide solution n. The solution is made up to 100 parts by volume with distilled water and, after filtration, filled into ampoules and sterilized.



   Instead of sterilization by heating, sterile solutions can also be obtained, if 0.08 part by weight of ether-methyl salt of p-oxybenzole acid and 0, is added to these before filtration. 01 part by weight of ether-propyl salt of p-oxybenzoic acid.


    

Claims (1)

Revendication. Claim. Procédé pour la préparation de solutions aqueuses stables de sels alcalins de l'acide 1-méthyl-5-isopropyl-5- allyl-barbiturique, consistant à additionner de lessive alcaline aqueuse l'acide 1-méthyl-5-isopropyl-5-allyl-bar- biturique en présence de diéthylamide acétique. Process for the preparation of stable aqueous solutions of alkali salts of 1-methyl-5-isopropyl-5-allyl-barbituric acid, comprising adding aqueous alkaline lye to 1-methyl-5-isopropyl-5-allyl acid -bar- bituric in the presence of acetic diethylamide.
BE462012D BE462012A (en)

Publications (1)

Publication Number Publication Date
BE462012A true BE462012A (en)

Family

ID=114531

Family Applications (1)

Application Number Title Priority Date Filing Date
BE462012D BE462012A (en)

Country Status (1)

Country Link
BE (1) BE462012A (en)

Similar Documents

Publication Publication Date Title
EP0316993B1 (en) Pharmaceutical compositions containing a derivative of 3-hydroxy-butanoic acid chosen among oligomers of this acid and among esters of this acid or of these oligomers with 1,3-butane-diol
JPS60136512A (en) Remedy and preventive for hyperlipemia
BE462012A (en)
EP0601911A1 (en) Acylamino acids obtained by acylation of protein hydrolipates and antimicrobial, antiparasitic or cosmetic compositions containing them
TR201809354T4 (en) 5 alpha androstan (alkyl) 3 beta, 5,6 beta triol injection and a method for the preparation thereof.
FI92015C (en) A method of preparing an injectable antiparasitic composition
RU2372904C2 (en) Alpha-lipoic (thioctic) acid composition, method for making thereof and therapy
FR2542999A1 (en) PROCESS FOR THE MANUFACTURE OF LIPOSOME CONTAINING ONE OR MORE STERYLGLUCOSIDES AND STERYLGLUCOSIDES MONOPALMITATES AND NOVEL PRODUCTS THUS OBTAINED
MC1485A1 (en) PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF POTENTIALIZED SULFONAMIDES
FR2516923A1 (en) NOVEL ORGANIC SALTS OF TETRAMISOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
NO334540B1 (en) Process for the preparation of a parasiticide for the eradication of parasites in farmed fish
IE47985B1 (en) Pharmaceutical compositions and their use in the prophylaxis and/or treatment of certain diseases
FR2507891A1 (en) Herpes, and other viruses having lipidic coatings, control - uses 2,6-di-tert.butyl-para-cresol with synergistic fatty acid deriv. emulsion initiator e.g. glycerol oleate
JPS5953423A (en) Preparation composition for rectal infusion containing cephalosporin compound
Moore et al. On the chemistry and bio-chemical and physiological properties of a sapo-glucoside obtained from the seeds of Bassia longifolia (mowrah seeds)
BE494334A (en)
FR3120523B1 (en) Process for incorporating salt marsh mother waters into cosmetic compositions, and cosmetic compositions thus prepared
CH167958A (en) A process for the preparation of a stable and sterilizable oily solution of bismuth mono-a-butylnormal thiolaurate.
CN121489861A (en) A concentrated solution of etoricoxib for injection and its preparation method
BE333357A (en)
BE483963A (en)
BE530472A (en)
BE541013A (en)
BE562589A (en)
CH169591A (en) A process for the preparation of a stable and sterilizable oily solution of tri-a-butylnormal bismuth thiolaurate.